Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants - Gabe - 2024 - Diabetes, Obesity and Metabolism US$ 26.64 Min. order: 1 piece ★★★★★ 4.4 (51 reviews) Sold : Login>>
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial US$ 24.31 Min. order: 1 piece ★★★★★ 4.5 (43 reviews) Sold : Login>>
In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results US$ 26.31 Min. order: 1 piece ★★★★★ 4.1 (28 reviews) Sold : Login>>
Trial Scorecard: REDEFINE 1 and 2 US$ 26.64 Min. order: 1 piece ★★★★★ 4.8 (162 reviews) Sold : Login>>
Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis US$ 24.49 Min. order: 1 piece ★★★★★ 4.0 (239 reviews) Sold : Login>>
Efficacy and safety of cagrilintide 2.4 mg in adults with overweight/obesity: Data from REDEFINE 1 US$ 21.99 Min. order: 1 piece ★★★★★ 4.6 (75 reviews) Sold : Login>>